S/N 09/605,054
Group 1619
#5

UNITED STATES PATENT AND TRADEMARK OFFICE

I, Norval O'CONNOR BSc, PhD,

translator to RWS Group plc, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England declare;

1. That I am a citizen of the United Kingdom of Great Britain and Northern Ireland.

2. That I am well acquainted with the French and English languages.

3. That the attached is, to the best of my knowledge and belief, a true translation into the English language of the accompanying copy of the specification filed with the application for a patent in France on 4 March 1996 under the number 96/02,662 and the official certificate attached hereto.

4. That I believe that all statements made herein of my own knowledge are true and that all statements made on information and belief are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application in the United States of America or any patent issuing thereon.

N O'Connor

For and on behalf of RWS Group plc

The 8th day of September 1999

FRENCH REPUBLIC

NIIP

NATIONAL INSTITUTE OF INDUSTRIAL PROPERTY

P A T E N T

UTILITY CERTIFICATE - CERTIFICATE OF ADDITION

OFFICIAL COPY

The Director of the National Institute of Industrial Property certifies that the attached document is a true copy of an application for industrial property titleright filed at the Institute.

Drawn up in Paris, 16 JAN. 1997

On behalf of the Director of the National
Institute of Industrial Property
The Divisional Head

(signature)

Yves CAMPENON

REGISTERED OFFICE
NATIONAL INSTITUTE OF INDUSTRIAL PROPERTY
26bis, rue de Saint Petersbourg
75800 PARIS Cédex 08
Telephone: (1) 42 94 52 52
Telefax: (1) 42 93 59 30

NATIONAL PUBLIC ESTABLISHMENT — CREATED BY LAW No. 51-444 OF 19 APRIL 1951

N I I P NATIONAL INSTITUTE OF INDUSTRIAL PROPERTY

Cerfa No. 55-1222

1

APPLICATION FOR THE GRANTING OF AN INDUSTRIAL PROPERTY TITLE/RIGHT*

a	X	PATENT
b		UTILITY CERTIFICATE
c		DIVISIONAL APPLICATION
d		CONVERSION OF A EUROPEAN PATENT APPLICATION

2 COMPULSORY OPTIONS at the time of filing (except for utility certificate)

THE APPLICANT REQUESTS THE DIFFERED FORMULATION OF THE DOCUMENTATION REPORT: [ ] YES [X] NO

IF THE OPTION SELECTED IS NO AND IF THE APPLICANT IS A PHYSICAL PERSON HE REQUESTS THE GRADUATED PAYMENT OF THE TAX ON THE DOCUMENTATION REPORT: [ ] YES [ ] NO

NATURE | NUMBER | DATE OF INITIAL APPLICATION

DATE OF SUBMISSION OF THE DOCUMENTS: 04. MAR 1996

for c and d, state exactly : the nature, number and date of the initial application

3 NAME AND ADDRESS OF THE APPLICANT OR THE REPRESENTATIVE TO WHOM ALL THE CORRESPONDENCE SHOULD BE ADDRESSED

Mrs Elisabeth THOURET-LEMAITRE
SYNTHELABO
Patents Department
P.O. Box 72
92352 LE PLESSIS ROBINSON CEDEX

NATIONAL REGISTRATION No.: 96/02.662

DATE OF FILING: 04 MARCH 1996

POSTAL CODE OF THE FILING PLACE: 75

4 DATE OF THE GENERAL POWER OF ATTORNEY

5 REFERENCE OF THE CORRESPONDENT: ETL/ct

6 TELEPHONE No. OF THE CORRESPONDENT: 45.37.55.07

7 TITLE OF THE INVENTION

Sustained-release pharmaceutical formulations containing mizolastine

8 APPLICANT: SURNAME AND CHRISTIAN NAMES (UNDERLINE THE SURNAME) OR NAME AND LEGAL CONSTITUTION

SYNTHELABO
Société Anonyme

SIREN NO.

9 COMPLETE ADDRESS

22 avenue Galilée
92350 LE PLESSIS ROBINSON

COUNTRY: FRANCE

10 NATIONALITY: French

TAXES PAID

[X] ON FILING

[X] ON DOCUMENTATION REPORT

[ ] ON CLAIM TO PRIORITY

[ ] ON CLAIM (from the 11th onwards)

11 INVENTOR(S) THE APPLICANT IS THE SOLE INVENTOR*

[ ] YES

If the answer is no see explanatory note [X] NO

12 IF THE APPLICANT IS A PHYSICAL PERSON NOT SUBJECT TO REVENUE COLLECTION, HE REQUESTS OR HAS REQUESTED REDUCTION OF THE TAXES [ ] YES [ ] NO

13 PRIORITY DECLARATION OR APPLICATION FOR THE BENEFIT OF THE FILING DATE OF A PRIOR APPLICATION

	COUNTRY OF ORIGIN	FILING DATE	NUMBER
			[redacted]

14 [ ] DIVISIONS PREVIOUS TO THE PRESENT APPLICATION

No.	No.	No.	No.

15 SIGNATURE OF THE APPLICANT OR HIS REPRESENTATIVE NAME AND POSITION OF SIGNATORY REGISTRATION NO.

(signature)
E. THOURET-LEMAITRE

SIGNATURE OF THE RECEIVING OFFICIAL

SIGNATURE AFTER REGISTRATION OF THE APPLICATION AT THE N.I.I.P

(illegible signature)

* Tick the relevant box

NIIP
NATIONAL INSTITUTE OF INDUSTRIAL PROPERTY
26bis, rue de Saint-Pétersbourg 75800 Paris Cédex Tel: (1)42 94 52 52 - Telecopier: (1)42 93 59 30
Patents Administrative Division

DESIGNATION OF THE INVENTOR

(if the applicant is not the inventor or the sole inventor)

National Registration No.

96/02,662

Title of the invention:
Sustained-release pharmaceutical formulations containing mizolastine

The undersigned
SYNTHELABO
22 avenue Galilée
92350 LE PLESSIS ROBINSON

designate(s) as inventor(s) (surname underlined, forenames, address)

- Maryvonne CHARIOT 22 ruelle des Néfliers 91620 LA VILLE DU BOIS
- Gareth LEWIS 39 avenue de Paris 91410 DOURDAN
- Jean MONTEL 3 rue le Val Sablon 78400 CHATOU

NOTE: In exceptional cases, the name of the inventor may be followed by that of the company to which he belongs (membership company) when the latter is other than the company which is the applicant or titleholder.

Date and signature(s) of the applicant(s) or of the representative

4 March 1996

(signature)

E. THOURET-LEMAITRE

BA 113/160392

The present invention relates to novel sustained-release pharmaceutical formulations containing 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]piperid-4-yl]methylamino]-pyrimidin-4-ol or 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]piperid-4-yl]methylamino]-pyrimidine-4(1H)-one, or mizolastine, as active principle.

Mizolastine is described in European patent EP 0,217,700.

Mizolastine binds to the H_1 histamine receptor and inhibits the degranulation of mastocytes in vitro and in vivo. It can thus be used for the treatment of respiratory, cutaneous or ocular allergies and various allergic manifestations.

During the oral administration of immediate-release formulations containing mizolastine, undesirable sedative effects have been observed which are associated with the existence of a high peak in the plasma.

Consequently, it was necessary to find formulations for an oral administration which have a profile of release of the active principle such that it is possible to obtain a lower peak in the plasma without decreasing the bioavailability.

The Applicant Company has based its research of such formulations on the study of the kinetics of dissolution of mizolastine. The reason for this is that

mizolastine is a weak base (pK 5.6) which is sparingly soluble in water (13 mg/l at neutral pH) but much more soluble at acidic pH (11 g/l at pH 3); the first gelatin capsules released 100 % of mizolastine over 30 minutes in a dissolution medium at pH 2 whereas only 40 % were dissolved at pH 6.8.

Moreover, the release of mizolastine from the sustained-release pharmaceutical form according to the invention did not need to be influenced by the differences in pH in the gastrointestinal tract.

The aim of the present invention is to propose formulations containing mizolastine whose dissolution profile is as follows:

- about 30 to 70 % of mizolastine dissolved in 1 hour,
- 100 % of mizolastine dissolved in 3 to 5 hours, and
- pH-independent profile.

The Applicant Company has shown that tablets containing a core formed of a sustained-release tablet containing mizolastine combined with a fatty matrix and with an acid of low pK, the said tablet being coated to prevent degradation of the product by light, are entirely suitable.

The tablets according to the invention contain from 1 mg to 25 mg of mizolastine. These doses correspond to concentrations of from 0.5 % to 12 % by weight of mizolastine.

The fatty matrix is made with hydrogenated castor oil or with hydrogenated lecithins or long-chain fatty acids such as behenic acid or triglycerides esterified with medium-chain fatty acids, for example C_8-C_{18} fatty acids.

The acid of low pK is chosen from maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acids in the form of racemates or isomers.

According to the invention, the acid particularly preferred is L-tartaric acid.

The weight ratio between the mizolastine and the acid of low pK should be between 0.3 and 1. With L-tartaric acid, this ratio is preferably equal to 0.5.

The tablets are prepared by granulation using the active principle, the agent constituting the fatty matrix, the acid of low pK and other excipients such as, for example, lactose, mannitol and sugars or similar sugar-alcohols, microcrystalline cellulose, starch, calcium phosphates and sulphates, polyvidone, and substituted celluloses such as hydroxypropyl-cellulose, hydroxypropylmethylcellulose or methylcellulose.

The granulation may be carried out in a wet phase, for example in the presence of water or alcohol, or may be performed by fusion or by compacting. The granulation step may optionally be left out and the tablets prepared by direct tableting of the mixture of the mizolastine and the excipients.

Anhydrous colloidal silica and magnesium stearate are added to the granules obtained and the mixture is tableted. The tablets are then covered with a coating film by spraying them with a coating solution in a machine with a fluidized-air bed or in a coating turbine.

The example which follows illustrates the invention without limiting it:

Tablet

	% (weight)
mizolastine	4.8
hydrogenated castor oil	12.0
lactose	60.0
microcrystalline cellulose	9.6
L-tartaric acid	9.6
polyvidone	2.9
anhydrous colloidal silica	0.2
magnesium stearate	0.9
purified water	Q.S.
Total	**100.0**

Coating

methylhydroxypropylcellulose	74.0
titanium dioxide (E171)	18.5
propylene glycol	7.5
purified water	Q.S.
Total	**100.0**

The dissolution profile obtained with a formulation according to the invention is given in Figure 1.

This profile gives about 50 % of product dissolved in 1 hour, 100 % of product dissolved in 3 to 5 hours, and it is independent of the pH.

The dissolution profile obtained with a formulation identical to that of the invention but containing no L-tartaric acid is given in Figure 2.

The plasma kinetics of a pharmaceutical form according to the invention containing 10 mg of mizolastine were studied in a healthy volunteer after a single oral administration, compared with a standard immediate-release gelatin capsule containing 10 mg of mizolastine.

Table 1 presents the kinetic parameters and Figure 3 the curves of the plasma kinetics, obtained respectively with each formulation; the plasma kinetics obtained with the pharmaceutical form according to the invention makes it possible to prevent any peak in the plasma without losing bioavailability.

The plasma kinetics of a pharmaceutical form according to the invention were also studied in comparison with the same formulation without L-tartaric acid.

The study was performed on twelve healthy volunteers after a single oral administration of a tablet according to the invention containing 10 mg of

mizolastine or the same tablet without L-tartaric acid.

Table 2 shows that the bioavailability of the formulation containing no L-tartaric acid represents only 43 % of that observed with the formulation according to the invention containing L-tartaric acid. The values of Cmax and the AUC values (0-∞) are respectively 1.5 and 2 times as high for the formulation containing L-tartaric acid as for that not containing any.

In addition, for the formulation with L-tartaric acid, the min.-max. variation indices are much lower, which suggests great uniformity in the release.

The results altogether show that the formulations according to the invention have:

- a pH-independent dissolution profile,
- an *in vivo* release which prevents any peak in the plasma,
- a bioavailability which is not decreased relative to an immediate-release formulation,
- lower variability of the plasma kinetics results.

CLAIMS

1. Sustained-release pharmaceutical formulation containing mizolastine, characterized in that it contains a core formed of a sustained-release tablet containing mizolastine combined with a fatty matrix and with an acid of low pK, the said tablet being coated.

2. Sustained-release pharmaceutical formulation according to Claim 1, characterized in that the weight ratio between the mizolastine and the acid of low pK is between 0.3 and 1.

3. Sustained-release pharmaceutical formulation according to either of Claims 1 and 2, characterized in that the fatty matrix is made with hydrogenated castor oil or with hydrogenated lecithins or long-chain fatty acids or triglycerides esterified with medium-chain fatty acids.

4. Sustained-release pharmaceutical formulation according to any one of Claims 1 to 3, characterized in that the acid of low pK is chosen from maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acids in the form of racemates or isomers.

5. Sustained-release pharmaceutical formulation according to any one of Claims 1 to 4, characterized in that the acid of low pK is L-tartaric acid.

6. Sustained-release pharmaceutical formulation according to Claim 5, characterized in that the ratio between the mizolastine and the L-tartaric acid is 0.5.

7. Formulation according to any one of Claims 1 to 6, characterized in that it contains from 1 to 25 mg of mizolastine.

Figure 1



Figure 2



Table 1

Formulation	Tmax (h)	Cmax (ng/ml)	t1/2β (h)	AUC(0-∞) ($ng.ml^{-1}.h$)	Frel
Gelatin capsule	0.9	398.4±22.7	14.8±1.5	1481±96	
Min-Max	0.5-1.5	202-529	6.7±33.1	1092-2717	
Tablet	1.4	234.2±13.7	14.5±1.2	1406.1±119	0.962
Min-Max	0.5-2.5	154-393	6.7-26.4	775-2458	
Statistical comparison	NS	p<0.001	NS	NS	

Figure 3



Table 2

Formulation	Tmax (h)	Cmax (ng/mL)	t1/2β (h)	AUC(0-t) $ng.ml^{-1}.h$	AUC(0-∞) $ng.ml^{-1}.h$	Frel
With L-tartaric acid	1.00	243.7±12.7	13.1±1.2	1347±117	1444±125	
Min-Max	0.75-2.5	166.5-314.1	5.9±19.4	734-1878	773-2011	
Without L-tartaric acid	0.75	147.0±28.8	12.9±1.1	601±134	635±139	0.43±0.08
Min-Max	0.5-2.5	4.5-285.4	5.1-17.6	27-1347	38-1397	0.03-0.87
Statistical comparison	NS	$p<0.05$	NS	$p<0.01$	$p<0.01$	